CME Stock Testing Price Floor – Buy Now?
CME (CME) stock should be on your watchlist. Here is why – it is currently trading in the support zone ($259.86 – $287.22), levels from which it has bounced meaningfully before. Since it first started trading, CME stock received buying interest at this level 5 times and subsequently went on to generate 7.0% in average peak returns.
| Peak Return | Days to Peak Return | |
|---|---|---|
| 4/30/2025 | 4.9% | 33 |
| 6/20/2025 | 4.8% | 45 |
| 8/20/2025 | 0.0% | 0 |
| 9/29/2025 | 4.7% | 46 |
| 12/11/2025 | 20.4% | 81 |
Yet, a support zone alone isn’t enough; rebounds are more likely when fundamentals, sentiment, and market conditions line up. How does that look for CME?
CME rebound probable on strong ops, sector growth.
CME’s Q1 2026 earnings beat estimates, showing 14.5% revenue growth and robust performance in clearing and market data. Trading near its 52-week low of $257.17 and below the 200-day MA, the stock appears undervalued given its strong operational execution. Analyst average targets around $305-$307 suggest significant upside. Industry tailwinds include heightened market volatility from global factors and expanding digital asset derivatives, bolstered by CME’s 24/7 crypto trading launch. Continued investment in cloud migration will improve efficiency. While the interest rate outlook is mixed, ongoing market activity drives derivatives volume, supporting a rebound.
How Do CME Financials Look Right Now?
- Revenue Growth: 7.5% LTM and 9.7% last 3-year average.
- Cash Generation: Nearly 64.1% free cash flow margin and 65.6% operating margin LTM.
- Recent Revenue Shocks: The minimum annual revenue growth in the last 3 years for CME was 7.5%.
- Valuation: CME stock trades at a PE multiple of 23.0
| CME | S&P Median | |
|---|---|---|
| Sector | Financials | – |
| Industry | Financial Exchanges & Data | – |
| PE Ratio | 23.0 | 23.7 |
|
|
||
| LTM* Revenue Growth | 7.5% | 7.4% |
| 3Y Average Annual Revenue Growth | 9.7% | 5.7% |
| Min Annual Revenue Growth Last 3Y | 7.5% | 0.5% |
|
|
||
| LTM* Operating Margin | 65.6% | 18.4% |
| 3Y Average Operating Margin | 64.1% | 18.3% |
| LTM* Free Cash Flow Margin | 64.1% | 14.4% |
*LTM: Last Twelve Months | For more details on CME fundamentals, read Buy or Sell CME Stock.
And What If The Support Breaks?
CME Group isn’t immune to big sell-offs. It dropped nearly 77% during the Global Financial Crisis, which is a huge hit. More recent shocks show it’s still vulnerable: 37% down in the Covid pandemic and 32% during the inflation shock. Even the 2018 correction wasn’t mild, with a 15% pullback. Fundamentals matter, but when markets turn sour, even solid names like CME take a hit.
But the risk is not limited to major market crashes. Stocks fall even when markets are in good shape – think events like earnings, business updates, and outlook changes. Read CME Dip Buyer Analyses to see how the stock has recovered from sharp dips in the past.
Still not sure about CME stock? Consider the portfolio approach.
Portfolios Are The Smarter Way To Invest
Stocks soar and sink – the key is staying invested. A balanced portfolio helps you ride market volatility, boosts gains, and reduces single stock risk.
Why settle for average market returns? The Trefis High Quality (HQ) Portfolio invests in a diverse group of 30 stocks that have collectively delivered stronger upside with reduced volatility compared to the broader indices. Discover the methodology behind these smoother, higher returns by checking the HQ Portfolio performance data.